Skip to main content
OpenTrials
Completed

NCT Number: NCT06659263

RE104 Clinical Lactation Study

The purpose of this study is to obtain data necessary to characterize the elimination of RE104 and metabolites from breastmilk of health lactating volunteers to support a regulatory assessment of when mothers can safely return to breastfeeding following a single-dose of RE104 for Injection.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 1

Primary location

PPD Inc

Las Vegas, Nevada, 89113, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Females between 18 and 45 years of age, at least 50 kgs, and a body mass index of 18-34 kg/m2
  • Has been breastfeeding or actively pumping for at least 4 weeks postpartum
  • Agrees to cease breastfeeding for duration of study (Day 14) and confirms infant is able to feed from a bottle at screening.
  • Willing and able to pump in order to maintain sufficient milk supply volumes for the study
  • Is not pregnant or planning to become pregnant during the study
  • Able to understand and adhere to study schedule and requirements and willing to sign an ICF
  • In good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead ECG results, and physical examination findings at screening

Exclusion criteria

  • Has mastitis or other condition that would prevent the collection of milk from one or both breasts
  • Active or medical history of significant mental disorder (including but not necessarily limited to major depression and anxiety disorders, bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and/or borderline personality disorder), or first-degree family history of psychosis or bipolar disorder
  • Medically significant condition or other concomitant condition or history rendering unsuitability for the study, in the judgement of the investigator
  • Has used or intends to use of prohibited medications
  • Has a known sensitivity or intolerance to hallucinogenic or psychedelic substances, or potential rescue medications

Treatment and study plan

RE104 for Injection

Drug

Single, subcutaneous dose of RE104 for Injection

Primary outcomes

  1. Area under the concentration-time curve from time zero to 24 hours post-dose (AUC0 24) for RE104 and 4-OH-DiPT in plasma and breast milk

    Time frame: Through 24 hours postdose

  2. Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) for RE104 and 4-OH-DiPT in plasma and breast milk

    Time frame: Through 168 hours postdose

  3. Maximum observed concentration (Cmax) for RE104 and 4-OH-DiPT in plasma and breast milk

    Time frame: Through 168 hours postdose

  4. Time to reach Cmax (tmax) for RE104 and 4-OH-DiPT in plasma and breast milk

    Time frame: Through 168 hours postdose

  5. Apparent total body clearance (CL/F) for RE104 in plasma

    Time frame: Through 168 hours postdose

  6. Apparent volume of distribution during the terminal phase (Vz/F) for RE104 in plasma

    Time frame: Through 168 hours postdose

  7. Apparent terminal elimination half-life (t1/2) for RE104 and 4-OH-DiPT in plasma

    Time frame: Through 168 hours postdose

  8. Milk to plasma (M/P) ratio for RE104 and 4-OH-DiPT in breast milk

    Time frame: Through 168 hours postdose

  9. Relative infant dose (RID) of RE104 and its active entity 4-OH-DiPT

    Time frame: Through 72 hours postdose

  10. Total RID of RE104 and its active entity 4-OH-DiPT

    Time frame: Through 168 hours postdose

Secondary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs) by frequency, severity and seriousness.

    Time frame: From dosing through study completion (post-dose follow-up is for 14 days)

    A treatment-emergent adverse event (TEAE) is defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a study drug.

  2. Area under the concentration-time curve from time zero to 24 hours post-dose (AUC0 24) for detectable/quantifiable RE104 metabolites in plasma and breast milk

    Time frame: Through 24 hours postdose

  3. Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) for detectable/quantifiable RE104 metabolites in plasma and breast milk

    Time frame: Through 168 hours postdose

  4. Maximum observed concentration (Cmax) for detectable/quantifiable RE104 metabolites in plasma and breast milk

    Time frame: Through 168 hours postdose

  5. Time to reach Cmax (tmax) for detectable/quantifiable RE104 metabolites in plasma and breast milk

    Time frame: Through 168 hours postdose

  6. Apparent terminal elimination half-life (t1/2) for detectable/quantifiable RE104 metabolites in plasma

    Time frame: Through 168 hours postdose

  7. Milk to plasma (M/P) ratio for detectable/quantifiable RE104 metabolites in breast milk

    Time frame: Through 168 hours postdose

  8. Amount of RE104 and its active entity 4 OH-DiPT excreted into breast milk (Ae) and amount of drug excreted into breast milk relative to dose (Fe)

    Time frame: Through 168 hours postdose

  9. Unbound and bound plasma concentrations of the RE104 active entity 4-OH-DiPT.

    Time frame: 1, 3 and 8 hours post-dose

Sponsors and collaborators

Lead sponsor

Reunion Neuroscience Inc

Industry

Registry information

Official study title

A Phase 1, Open-label, Single Dose Study to Evaluate the Concentration of RE104 and Its Major Metabolites in Breast Milk and Plasma of Healthy Lactating Women.

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Oct 26, 2024
Registry last updated
Jun 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.